> top > docs > PubMed:32352535 > annotations

PubMed:32352535 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid-OGER-BB

Id Subject Object Predicate Lexical cue
T1 0-8 SP_7 denotes COVID-19
T2 17-38 UBERON:0004535 denotes cardiovascular system
T3 118-129 NCBITaxon:11118 denotes coronavirus
T4 139-147 SP_7 denotes COVID-19
T5 169-179 SP_7 denotes SARS-CoV-2
T6 295-303 SP_7 denotes COVID-19
T7 383-391 SP_7 denotes COVID-19
T8 414-419 UBERON:0000170 denotes lungs
T9 429-441 UBERON:0005169 denotes interstitial
T10 458-500 SP_10 denotes severe acute respiratory distress syndrome
T11 471-482 UBERON:0001004 denotes respiratory
T12 534-540 UBERON:0000062 denotes organs
T13 559-580 UBERON:0004535 denotes cardiovascular system
T14 704-718 UBERON:0004535 denotes cardiovascular
T15 760-769 UBERON:0002048 denotes pulmonary
T16 841-847 UBERON:0002081 denotes atrial
T17 862-873 UBERON:0002082 denotes ventricular
T18 895-906 UBERON:0002082 denotes ventricular
T19 922-929 UBERON:0000948 denotes cardiac
T20 979-983 PR:P23693 denotes cTnI
T21 1042-1047 UBERON:0000948 denotes heart
T22 1057-1066 UBERON:0002048 denotes pulmonary
T23 1108-1119 GO:0050817 denotes coagulation
T24 1144-1148 PR:000014459 denotes SARS
T25 1144-1154 SP_7 denotes SARS-CoV-2
T26 1166-1177 GO:0006508 denotes proteolytic
T27 1178-1186 MOP:0000780 denotes cleavage
T28 1194-1203 PG_1 denotes S protein
T29 1239-1252 GO:0016020 denotes transmembrane
T30 1253-1284 PR:000003622 denotes angiotensin-converting enzyme 2
T31 1253-1284 PG_10 denotes angiotensin-converting enzyme 2
T32 1286-1290 PR:000003622 denotes ACE2
T33 1286-1290 G_3 denotes ACE2
T34 1286-1290 PG_10 denotes ACE2
T35 1295-1304 SO:0000853 denotes homologue
T36 1321-1339 CL:0002063 denotes type 2 pneumocytes
T37 1341-1352 CL:0000235 denotes macrophages
T38 1354-1366 UBERON:0014930 denotes perivascular
T39 1367-1376 CL:0000669 denotes pericytes
T40 1382-1396 CL:0000746 denotes cardiomyocytes
T41 1415-1425 UBERON:0002349 denotes myocardial
T42 1450-1461 UBERON:0001986 denotes endothelial
T43 1526-1536 UBERON:0002349 denotes myocardial
T44 1560-1564 G_3 denotes ACE2
T45 1560-1564 PG_10 denotes ACE2
T46 1560-1564 PR:000003622 denotes ACE2
T47 1582-1587 NCBITaxon:10239 denotes viral
T48 1628-1638 CHEBI:35222 denotes inhibitors
T49 1628-1638 CHEBI:35222 denotes inhibitors
T50 1654-1662 CHEBI:48561 denotes receptor
T51 1654-1662 CHEBI:48561 denotes receptor
T52 1757-1762 PR:000013883 denotes renin
T53 1801-1811 CHEBI:35222 denotes inhibitors
T54 1801-1811 CHEBI:35222 denotes inhibitors
T55 1835-1843 SP_7 denotes COVID-19
T56 1853-1859 UBERON:0002405 denotes immune
T57 1853-1859 GO:0006955 denotes immune
T58 1877-1886 GO:0006955 denotes responses
T59 1939-1943 PR:000001317 denotes IL-7
T60 1945-1950 PR:000001383 denotes IL-22
T61 1952-1957 PR:000001092 denotes IL-17
T62 2003-2011 SP_7 denotes COVID-19
T63 2058-2065 UBERON:0000948 denotes cardiac
T64 2098-2109 GO:0050817 denotes coagulation
T65 2169-2176 UBERON:0000948 denotes cardiac
T66 2196-2204 SP_7 denotes COVID-19
T67 2295-2309 UBERON:0004535 denotes cardiovascular
T68 2316-2330 UBERON:0004535 denotes Cardiovascular
T69 2385-2395 DG_28 denotes remdesivir
T70 2397-2408 DG_10 denotes chloroquine
T71 2397-2408 CHEBI:3638 denotes chloroquine
T72 2397-2408 CHEBI:3638 denotes chloroquine
T73 2410-2428 DG_20 denotes hydroxychloroquine
T74 2410-2428 CHEBI:5801 denotes hydroxychloroquine
T75 2410-2428 CHEBI:5801 denotes hydroxychloroquine
T76 2430-2441 DG_35 denotes tocilizumab
T77 2443-2452 DG_29 denotes ribavirin
T78 2471-2480 DG_23 denotes lopinavir
T79 2481-2490 DG_30 denotes ritonavir
T80 2535-2540 SP_6 denotes human
T81 2535-2540 NCBITaxon:9606 denotes human
T82 2553-2557 G_3 denotes ACE2
T83 2553-2557 PG_10 denotes ACE2
T84 2553-2557 PR:000003622 denotes ACE2

hydroxychloroquine

Id Subject Object Predicate Lexical cue hp_id
T1 429-453 Phenotype denotes interstitial pneumonitis http://purl.obolibrary.org/obo/HP_0006515
T2 471-491 Phenotype denotes respiratory distress http://purl.obolibrary.org/obo/HP_0002098
T3 590-606 Phenotype denotes severe infection http://purl.obolibrary.org/obo/HP_0032169
T4 704-726 Phenotype denotes cardiovascular disease http://purl.obolibrary.org/obo/HP_0001626
T5 728-740 Phenotype denotes hypertension http://purl.obolibrary.org/obo/HP_0000822
T6 783-789 Phenotype denotes cancer http://purl.obolibrary.org/obo/HP_0002664
T7 829-839 Phenotype denotes arrhythmia http://purl.obolibrary.org/obo/HP_0011675
T8 841-860 Phenotype denotes atrial fibrillation http://purl.obolibrary.org/obo/HP_0005110
T9 895-919 Phenotype denotes ventricular fibrillation http://purl.obolibrary.org/obo/HP_0001663
T10 947-963 Phenotype denotes highly sensitive http://purl.obolibrary.org/obo/HP_0041092
T11 1029-1040 Phenotype denotes myocarditis http://purl.obolibrary.org/obo/HP_0012819
T12 1042-1055 Phenotype denotes heart failure http://purl.obolibrary.org/obo/HP_0001635
T13 1057-1075 Phenotype denotes pulmonary embolism http://purl.obolibrary.org/obo/HP_0002204
T14 1081-1119 Phenotype denotes disseminated intravascular coagulation http://purl.obolibrary.org/obo/HP_0005521
T15 1121-1124 Phenotype denotes DIC http://purl.obolibrary.org/obo/HP_0005521
T16 1450-1473 Phenotype denotes endothelial dysfunction http://purl.obolibrary.org/obo/HP_0032654
T17 1526-1547 Phenotype denotes myocardial infarction http://purl.obolibrary.org/obo/HP_0001658
T18 1549-1551 Phenotype denotes MI http://purl.obolibrary.org/obo/HP_0001658
T19 1903-1917 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-107 Sentence denotes COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.
T2 108-234 Sentence denotes The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades.
T3 235-376 Sentence denotes We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies.
T4 377-581 Sentence denotes While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system.
T5 582-662 Sentence denotes Risk of severe infection and mortality increase with advancing age and male sex.
T6 663-790 Sentence denotes Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer.
T7 791-1126 Sentence denotes The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC).
T8 1127-1397 Sentence denotes Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes.
T9 1398-1553 Sentence denotes This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI).
T10 1554-1696 Sentence denotes While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis.
T11 1697-1746 Sentence denotes Hence, patients should not discontinue their use.
T12 1747-1844 Sentence denotes Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19.
T13 1845-2012 Sentence denotes Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19.
T14 2013-2219 Sentence denotes Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications.
T15 2220-2315 Sentence denotes Preventive measures (social distancing and social isolation) also increase cardiovascular risk.
T16 2316-2582 Sentence denotes Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.
T1 0-107 Sentence denotes COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.
T2 108-234 Sentence denotes The novel coronavirus disease (COVID-19) outbreak, caused by SARS-CoV-2, represents the greatest medical challenge in decades.
T3 235-376 Sentence denotes We provide a comprehensive review of the clinical course of COVID-19, its comorbidities, and mechanistic considerations for future therapies.
T4 377-581 Sentence denotes While COVID-19 primarily affects the lungs, causing interstitial pneumonitis and severe acute respiratory distress syndrome (ARDS), it also affects multiple organs, particularly the cardiovascular system.
T5 582-662 Sentence denotes Risk of severe infection and mortality increase with advancing age and male sex.
T6 663-790 Sentence denotes Mortality is increased by comorbidities: cardiovascular disease, hypertension, diabetes, chronic pulmonary disease, and cancer.
T7 791-1126 Sentence denotes The most common complications include arrhythmia (atrial fibrillation, ventricular tachyarrhythmia, and ventricular fibrillation), cardiac injury [elevated highly sensitive troponin I (hs-cTnI) and creatine kinase (CK) levels], fulminant myocarditis, heart failure, pulmonary embolism, and disseminated intravascular coagulation (DIC).
T8 1127-1397 Sentence denotes Mechanistically, SARS-CoV-2, following proteolytic cleavage of its S protein by a serine protease, binds to the transmembrane angiotensin-converting enzyme 2 (ACE2) -a homologue of ACE-to enter type 2 pneumocytes, macrophages, perivascular pericytes, and cardiomyocytes.
T9 1398-1553 Sentence denotes This may lead to myocardial dysfunction and damage, endothelial dysfunction, microvascular dysfunction, plaque instability, and myocardial infarction (MI).
T10 1554-1696 Sentence denotes While ACE2 is essential for viral invasion, there is no evidence that ACE inhibitors or angiotensin receptor blockers (ARBs) worsen prognosis.
T11 1697-1746 Sentence denotes Hence, patients should not discontinue their use.
T12 1747-1844 Sentence denotes Moreover, renin-angiotensin-aldosterone system (RAAS) inhibitors might be beneficial in COVID-19.
T13 1845-2012 Sentence denotes Initial immune and inflammatory responses induce a severe cytokine storm [interleukin (IL)-6, IL-7, IL-22, IL-17, etc.] during the rapid progression phase of COVID-19.
T14 2013-2219 Sentence denotes Early evaluation and continued monitoring of cardiac damage (cTnI and NT-proBNP) and coagulation (D-dimer) after hospitalization may identify patients with cardiac injury and predict COVID-19 complications.
T15 2220-2315 Sentence denotes Preventive measures (social distancing and social isolation) also increase cardiovascular risk.
T16 2316-2582 Sentence denotes Cardiovascular considerations of therapies currently used, including remdesivir, chloroquine, hydroxychloroquine, tocilizumab, ribavirin, interferons, and lopinavir/ritonavir, as well as experimental therapies, such as human recombinant ACE2 (rhACE2), are discussed.